| Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 2585 | 2013 |
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with … M Peeters, TJ Price, A Cervantes, AF Sobrero, M Ducreux, Y Hotko, ... Journal of clinical oncology 28 (31), 4706-4713, 2010 | 1245 | 2010 |
| Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for … KS Oliner, JY Douillard, S Siena, J Tabernero, RL Burkes, ME Barugel, ... Journal of Clinical Oncology 31 (15_suppl), 3511-3511, 2013 | 96 | 2013 |
| Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer JR Hecht, JY Douillard, L Schwartzberg, A Grothey, S Kopetz, A Rong, ... Cancer treatment reviews 41 (8), 653-659, 2015 | 82 | 2015 |
| 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) M Peeters, T Price, Y Hotko, A Cervantes, M Ducreux, T André, E Chan, ... EJC Supplements 3 (7), 10, 2009 | 67 | 2009 |
| RAS mutations in colorectal cancer JY Douillard, A Rong, R Sidhu The New England journal of medicine 369 (22), 2159-2160, 2013 | 64 | 2013 |
| Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials R Sidhu, A Rong, S Dahlberg Clinical Cancer Research 19 (5), 969-976, 2013 | 58 | 2013 |
| Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy T Xu, Y Fang, A Rong, J Wang BMC medical research methodology 15, 1-7, 2015 | 37 | 2015 |
| Palifermin treatment of mucositis in transplant patients reduces health resource use: phase 3 results C Emmanouilides, R Spielberger, P Stiff, A Rong Blood 102 (11), 251a, 2003 | 29 | 2003 |
| Weighted log‐rank test for time‐to‐event data in immunotherapy trials with random delayed treatment effect and cure rate S Liu, C Chu, A Rong Pharmaceutical statistics 17 (5), 541-554, 2018 | 23 | 2018 |
| Biomarker threshold adaptive designs for survival endpoints G Diao, J Dong, D Zeng, C Ke, A Rong, JG Ibrahim Journal of biopharmaceutical statistics 28 (6), 1038-1054, 2018 | 11 | 2018 |
| TITE‐gBOIN: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding accounting for toxicity grades K Takeda, Q Xia, S Liu, A Rong Pharmaceutical Statistics 21 (2), 496-506, 2022 | 10 | 2022 |
| Estimation of delay time in survival data with delayed treatment effect W Li, SYP Chen, A Rong Journal of Biopharmaceutical Statistics 29 (2), 229-243, 2019 | 9 | 2019 |
| Palifermin reduces severe oral mucositis (OM), improves patient quality of life, and reduces health resource use in patients with hematologic malignancies receiving high-dose … W Bensinger, D Weisdorf, T Gentile, A Cesano, D Elhardt, ... Biology of Blood and Marrow Transplantation 10, 31, 2004 | 7 | 2004 |
| Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers K Takeda, S Liu, A Rong Statistics in Medicine 41 (2), 298-309, 2022 | 5 | 2022 |
| Study design of single‐arm phase II immunotherapy trials with long‐term survivors and random delayed treatment effect C Chu, S Liu, A Rong Pharmaceutical Statistics 19 (4), 358-369, 2020 | 5 | 2020 |
| Long-Term Survival Is Comparable between Palifermin-Treated and Placebo-Treated Patients (Pts) with Hematologic Malignancies (HM) Undergoing High-Dose Chemotherapy and Total … R Spielberger, C Emmanouilides, W Bensinger, A Rong, A Cesano, P Stiff Blood, The Journal of the American Society of Hematology 106 (11), 2925-2925, 2005 | 5 | 2005 |
| Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects G Diao, D Zeng, JG Ibrahim, A Rong, O Lee, K Zhang, Q Chen Journal of biopharmaceutical statistics 27 (6), 933-944, 2017 | 4 | 2017 |
| The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab … J Wang, J Dong, G Hechmati, A Rong, G Maglinte, BL Barber, ... Journal of Clinical Oncology 33 (15_suppl), 3543-3543, 2015 | 3 | 2015 |
| Evaluation of KRAS, NRAS, and BRAF mutations in PRIME: panitumumab with FOLFOX4 as first-line treatment in metastatic colorectal cancer (mCRC) K Oliner, JY Douillard, S Siena, J Tabernero, R Burkes, M Barugel, ... Annals of Oncology 24, iv23-iv24, 2013 | 3 | 2013 |
